<DOC>
	<DOCNO>NCT00294060</DOCNO>
	<brief_summary>The P3 Study United States post market study gather data clinical status , primary indication , device therapy choice , clinical management outcomes patient implantable pacemaker .</brief_summary>
	<brief_title>P3 : Pacemaker Patient Profiling Study</brief_title>
	<detailed_description />
	<mesh_term>Bradycardia</mesh_term>
	<criteria>Patient meet Class I / Class II indication pace Patient implant one follow marketapproved single dual chamber Medtronic device : EnRhythm™ , EnPulse® , Kappa® 700 , Kappa® 900 , Vitatron Clarity™ , Vitatron Selection® AFm , Vitatron CSeries , Vitatron TSeries , AT500™ DDDR Pacing System Patient enrol device cardiovascular drug study affect treatment and/or study device program Patient whose life expectancy less two year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Pacemaker</keyword>
	<keyword>Bradycardia</keyword>
</DOC>